Page last updated: 2024-12-06
n-4-tosylglycine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
N-4-tosylglycine: facilitates insulin release [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 70653 |
| CHEMBL ID | 287486 |
| SCHEMBL ID | 760439 |
| MeSH ID | M0133267 |
Synonyms (57)
| Synonym |
|---|
| BB 0219377 |
| nsc25821 |
| nsc-25821 |
| 1080-44-0 |
| CBDIVE_003168 |
| OPREA1_169137 |
| EU-0000679 |
| n-p-tosylglycine, 97% |
| CHEMBL287486 , |
| STL087629 |
| n-[(4-methylphenyl)sulfonyl]glycine |
| 2-[(4-methylphenyl)sulfonylamino]acetic acid |
| AKOS001060050 |
| n-p-tosylglycine |
| HMS1607N08 |
| (toluene-4-sulfonylamino)-acetic acid |
| bdbm50016567 |
| A801797 |
| 2-[(4-methylphenyl)sulfonylamino]ethanoic acid |
| n-(p-toluenesulfonyl)glycine |
| n-tosylglycine |
| tos-gly-oh |
| T2803 |
| 2-{[(4-methylphenyl)sulfonyl]amino}acetic acid |
| n-4-tosylglycine |
| glycine, n-((4-methylphenyl)sulfonyl)- |
| nsc 25821 |
| FT-0633313 |
| BBL022967 |
| tosyl-glycine |
| 2-(4-methylphenylsulfonamido)acetic acid |
| F0020-0600 |
| AB00275149-04 |
| AM81796 |
| n-(toluene-4-sulfonyl)-glycine |
| SCHEMBL760439 |
| ([(4-methylphenyl)sulfonyl]amino)acetic acid # |
| n-p-toluenesulfonyl-dl-glycine |
| glycine, n-p-toluenesulfonyl- |
| glycine, n-[(4-methylphenyl)sulfonyl]- |
| DTXSID00148355 |
| mfcd00045898 |
| J-002047 |
| n-[(4-methylphenyl)sulfonyl]glycne |
| J-523301 |
| SR-01000393622-1 |
| sr-01000393622 |
| tosylglycin |
| SY033142 |
| Z45658546 |
| CS-0046764 |
| DS-13625 |
| n-(toluene-4-sulfonyl)glycine |
| NCGC00325861-01 |
| 2-(4-methylbenzenesulfonamido)acetic acid |
| EN300-00514 |
| HY-W053699 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (5)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Carbonic anhydrase 12 | Homo sapiens (human) | IC50 (µMol) | 8.5700 | 0.0057 | 1.3990 | 8.5700 | AID1180164 |
| Carbonic anhydrase 1 | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0058 | 2.1410 | 7.9000 | AID1180159 |
| Carbonic anhydrase 1 | Homo sapiens (human) | Ki | 120.1000 | 0.0000 | 1.3726 | 10.0000 | AID1254397 |
| Carbonic anhydrase 2 | Homo sapiens (human) | IC50 (µMol) | 3.6230 | 0.0002 | 1.1060 | 8.3000 | AID1180161 |
| Carbonic anhydrase 2 | Homo sapiens (human) | Ki | 143.8000 | 0.0000 | 0.7236 | 9.9200 | AID1254398 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 32.0000 | 0.0004 | 1.8773 | 10.0000 | AID34970 |
| Carbonic anhydrase 9 | Homo sapiens (human) | IC50 (µMol) | 0.2170 | 0.0003 | 0.6302 | 9.3900 | AID1180163 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (17)
Molecular Functions (7)
Ceullar Components (11)
Bioassays (11)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1180163 | Inhibition of CA-9 (unknown origin) after 15 mins by CO2 hydration assay | 2014 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15 | Flow synthesis and biological activity of aryl sulfonamides as selective carbonic anhydrase IX and XII inhibitors. |
| AID1180161 | Inhibition of CA-2 (unknown origin) after 15 mins by CO2 hydration assay | 2014 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15 | Flow synthesis and biological activity of aryl sulfonamides as selective carbonic anhydrase IX and XII inhibitors. |
| AID1180160 | Inhibition of CA-1 (unknown origin) at 10 uM after 15 mins by CO2 hydration assay | 2014 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15 | Flow synthesis and biological activity of aryl sulfonamides as selective carbonic anhydrase IX and XII inhibitors. |
| AID1254397 | Inhibition of cytosolic carbonic anhydrase 1 esterase activity isolated from human erythrocytes using 4-nitrophenylacetate as substrate measured over 3 mins by spectrophotometric analysis | 2015 | Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23 | Carbonic anhydrase inhibitors: Design, synthesis, kinetic, docking and molecular dynamics analysis of novel glycine and phenylalanine sulfonamide derivatives. |
| AID34970 | Inhibitory concentration against aldose reductase obtained from rat lens | 1989 | Journal of medicinal chemistry, Jan, Volume: 32, Issue:1 | N- and 2-substituted N-(phenylsulfonyl)glycines as inhibitors of rat lens aldose reductase. |
| AID1254398 | Inhibition of cytosolic carbonic anhydrase 2 esterase activity isolated from human erythrocytes using 4-nitrophenylacetate as substrate measured over 3 mins by spectrophotometric analysis | 2015 | Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23 | Carbonic anhydrase inhibitors: Design, synthesis, kinetic, docking and molecular dynamics analysis of novel glycine and phenylalanine sulfonamide derivatives. |
| AID1180159 | Inhibition of CA-1 (unknown origin) after 15 mins by CO2 hydration assay | 2014 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15 | Flow synthesis and biological activity of aryl sulfonamides as selective carbonic anhydrase IX and XII inhibitors. |
| AID1254401 | Competitive inhibition of cytosolic carbonic anhydrase 1 esterase activity isolated from human erythrocytes in presence of 4-nitrophenylacetate | 2015 | Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23 | Carbonic anhydrase inhibitors: Design, synthesis, kinetic, docking and molecular dynamics analysis of novel glycine and phenylalanine sulfonamide derivatives. |
| AID1180164 | Inhibition of CA-12 (unknown origin) after 15 mins by CO2 hydration assay | 2014 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15 | Flow synthesis and biological activity of aryl sulfonamides as selective carbonic anhydrase IX and XII inhibitors. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.85
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.85) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||